Schwann cells as a therapeutic target for peripheral neuropathies

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 801-806

  Lehmann, Helmar C ^a,b   Höke, Ahmet ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Myelination; Nerve injury; Peripheral nerve; Regeneration; Schwann cells

Indexed keywords

ANTIGESTAGEN; ASCORBIC ACID; DIDANOSINE; GROWTH FACTOR; NERVE GROWTH FACTOR; NEUROHORMONE; NEUROTROPHIN; NEUROTROPHIN 3; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT NERVE GROWTH FACTOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE;

ANTIRETROVIRAL TOXIC NEUROPATHY; ARTICLE; CELL TRANSPLANTATION; CLINICAL TRIAL; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HEMOGLOBIN BLOOD LEVEL; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MYELIN SHEATH; NERVE REGENERATION; NEUROPATHY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; SCHWANN CELL; SIDE EFFECT;

EID: 78649258947     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237412     Document Type: Article

References (98)

1. Chen, Z.; Yu, W.; Strickland, S. Peripheral regeneration. Annu.Rev. Neurosci., 2007, 30, 209-233.
2. Hoke, A. Mechanisms of disease: what factors limit the success ofperipheral nerve regeneration in humans? Nat. Clin. Pract. Neurol., 2006, 2(8), 448-454.
3. Sherman, D.; Brophy, P. Mechanisms of axon ensheathment andmyelin growth. Nat. Rev. Neurosci., 2005, 6(9), 683-690.
4. Sulaiman, O.; Gordon, T. Effects of short and long-term Schwanncell denervation on peripheral nerve regeneration, myelination, andsize. Glia, 2000, 32(3), 234-246.
5. Fu, S.; Gordon, T. The cellular and molecular basis of peripheralnerve regeneration. Mol. Neurobiol., 1997, 14(1-2), 67-116.
6. Bunge, R.P.; Bunge, M.B.; Eldridge, C.F. Linkage between axonalensheathment and basal lamina production by Schwann cells. Annu.Rev. Neurosci., 1986, 9, 305-328.
7. Bunge, M.B.; Clark, M.B.; Dean, A.C.; Eldridge, C.F.; Bunge, R.P. Schwann cell function depends upon axonal signals and basallamina components. Ann. NY Acad. Sci., 1990, 580, 281-287.
8. Keswani, S.; Pardo, C.; Cherry, C.; Hoke, A.; McArthur, J. HIVassociatedsensory neuropathies. AIDS, 2002, 16(16), 2105-2117.
9. Cornblath, D.; Hoke, A. Recent advances in HIV neuropathy. Curr.Opin. Neurol., 2006, 19(5), 446-450.
10. McArthur, J.; Brew, B.; Nath, A. Neurological complications ofHIV infection. Lancet Neurol., 2005, 4(9), 543-555.
11. Sacktor, N. The epidemiology of human immunodeficiency virusassociatedneurological disease in the era of highly activeantiretroviral therapy. J. Neurovirol., 2002, 8(Suppl 2), 115-121.
12. Childs, E.; Lyles, R.; Selnes, O.; Chen, B.; Miller, E.; Cohen, B.; Becker, J.; Mellors, J.; McArthur, J. Plasma viral load and CD4lymphocytes predict HIV-associated dementia and sensoryneuropathy. Neurology, 1999, 52(3), 607-613.
13. Simpson, D.; Haidich, A.; Schifitto, G.; Yiannoutsos, C.; Geraci, A.; McArthur, J.; Katzenstein, D. Severity of HIV-associatedneuropathy is associated with plasma HIV-1 RNA levels. AIDS, 2002, 16(3), 407-412.
14. Schifitto, G.; McDermott, M.; McArthur, J.; Marder, K.; Sacktor, N.; McClernon, D.; Conant, K.; Cohen, B.; Epstein, L.; Kieburtz, K. Markers of immune activation and viral load in HIV-associatedsensory neuropathy. Neurology, 2005, 64(5), 842-848.
15. Simpson, D.; Kitch, D.; Evans, S.; McArthur, J.; Asmuth, D.; Cohen, B.; Goodkin, K.; Gerschenson, M.; So, Y.; Marra, CM.; Diaz-Arrastia, R.; Shriver, S.; Millar, L.; Clifford, D.B.; ACTGA5117 Study Group. HIV neuropathy natural history cohort study:assessment measures and risk factors. Neurology, 2006, 66(11), 1679-1687.
16. Zhou, L.; Kitch, D.; Evans, S.; Hauer, P.; Raman, S.; Ebenezer, G.; Gerschenson, M.; Marra, C.; Valcour, V.; Diaz-Arrastia, R.; Goodkin, K.; Millar, L.; Shriver, S.; Asmuth, D.M.; Clifford, D.B.; Simpson, D.M.; McArthur, J.C.; NARC and ACTG A5117 StudyGroup. Correlates of epidermal nerve fiber densities in HIVassociateddistal sensory polyneuropathy. Neurology, 2007, 68(24), 2113-2119.
17. Bradley, W.; Shapshak, P.; Delgado, S.; Nagano, I.; Stewart, R.; Rocha, B. Morphometric analysis of the peripheral neuropathy ofAIDS. Muscle Nerve, 1998, 21(9), 1188-1195.
18. Pardo, C.; McArthur, J.; Griffin, J. HIV neuropathy: insights in thepathology of HIV peripheral nerve disease. J. Peripher. Nerv. Syst., 2001, 6(1), 21-27.
19. Lehmann, H.C.; Kohne, A.; zu Horste, M.G.; Dehmel, T.; Kiehl, O.; Hartung, H.P.; Kastenbauer, S.; Kieseier, B.C. Role of nitricoxide as mediator of nerve injury in inflammatory neuropathies. J.Neuropathol. Exp. Neurol., 2007, 66(4), 305-312.
20. Thomas, F.; Chalk, C.; Lalonde, R.; Robitaille, Y.; Jolicoeur, P. Expression of human immunodeficiency virus type 1 in the nervoussystem of transgenic mice leads to neurological disease. J. Virol., 1994, 68(11), 7099-7107.
21. Nagano, I.; Shapshak, P.; Yoshioka, M.; Xin, K.; Nakamura, S.; Bradley, W. Increased NADPH-diaphorase reactivity and cytokineexpression in dorsal root ganglia in acquired immunodeficiencysyndrome. J. Neurol. Sci., 1996, 136(1-2), 117-128.
22. Yoshioka, M.; Shapshak, P.; Srivastava, A.; Stewart, R.; Nelson, S.; Bradley, W.; Berger, J.; Rhodes, R.; Sun, N.; Nakamura, S. Expression of HIV-1 and interleukin-6 in lumbosacral dorsal rootganglia of patients with AIDS. Neurology, 1994, 44(6), 1120-1130.
23. Keswani, S.C.; Polley, M.; Pardo, C.A.; Griffin, J.W.; McArthur, J.C.; Hoke, A. Schwann cell chemokine receptors mediate HIV-1gp120 toxicity to sensory neurons. Ann. Neurol., 2003, 54(3), 287-296.
24. Melli, G.; Keswani, S.; Fischer, A.; Chen, W.; Höke, A. Spatiallydistinct and functionally independent mechanisms of axonaldegeneration in a model of HIV-associated sensory neuropathy.Brain, 2006, 129(Pt 5), 1330-1338.
25. Keswani, S.; Leitz, G.; Hoke, A. Erythropoietin is neuroprotectivein models of HIV sensory neuropathy. Neurosci. Lett., 2004, 371(2-3), 102-105.
26. Robinson, B.; Li, Z.; Nath, A. Nucleoside reverse transcriptaseinhibitors and human immunodeficiency virus proteins causeaxonal injury in human dorsal root ganglia cultures. J. Neurovirol., 2007, 13(2), 160-167.
27. Apostolski, S.; McAlarney, T.; Hays, A.; Latov, N. Complementdependent cytotoxicity of sensory ganglion neurons mediated bythe gp120 glycoprotein of HIV-1. Immunol. Invest., 1994, 23(1), 47-52.
28. Keswani, S.C.; Buldanlioglu, U.; Fischer, A.; Reed, N.; Polley, M.; Liang, H.; Zhou, C.; Jack, C.; Leitz, G.J.; Hoke, A. A novelendogenous erythropoietin mediated pathway prevents axonaldegeneration. Ann. Neurol., 2004, 56(6), 815-826.
29. Kaul, S.; Dandekar, K.; Schilling, B.; Barbhaiya, R. Toxicokineticsof 2', 3'-didehydro-3'-deoxythymidine, stavudine (D4T). DrugMetab. Dispos., 1999, 27(1), 1-12.
30. Warner, W.; Bregman, C.; Comereski, C.; Arezzo, J.; Davidson, T.; Knupp, C.; Kaul, S.; Durham, S.; Wasserman, A.; Frantz, J. Didanosine (ddl) and stavudine (d4T): absence of peripheralneurotoxicity in rabbits. Food Chem. Toxicol., 1995, 33(12), 1047-1050.
31. Keswani, S.; Jack, C.; Zhou, C.; Höke, A. Establishment of arodent model of HIV-associated sensory neuropathy. J. Neurosci., 2006, 26(40), 10299-10304.
32. Nave, K.; Sereda, M.; Ehrenreich, H. Mechanisms of disease:inherited demyelinating neuropathies--from basic to clinicalresearch. Nat. Clin. Pract. Neurol., 2007, 3(8), 453-464.
33. Meyer Zu Hörste, G.; Nave, K. Animal models of inheritedneuropathies. Curr. Opin. Neurol., 2006, 19(5), 464-473.
34. Berger, P.; Niemann, A.; Suter, U. Schwann cells and thepathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease). Glia, 2006, 54(4), 243-257.
35. Suter, U.; Snipes, G. Biology and genetics of hereditary motor andsensory neuropathies. Annu. Rev. Neurosci., 1995, 18, 45-75.
36. Fortun, J.; Go, J.; Li, J.; Amici, S.; Dunn, W.J.; Notterpek, L. Alterations in degradative pathways and protein aggregation in aneuropathy model based on PMP22 overexpression. Neurobiol.Dis., 2006, 22(1), 153-164.
37. Fortun, J.; Li, J.; Go, J.; Fenstermaker, A.; Fletcher, B.; Notterpek, L. Impaired proteasome activity and accumulation of ubiquitinatedsubstrates in a hereditary neuropathy model. J. Neurochem., 2005, 92(6), 1531-1541.
38. Sahenk, Z.; Nagaraja, H.; McCracken, B.; King, W.; Freimer, M.; Cedarbaum, J.; Mendell, J. NT-3 promotes nerve regeneration andsensory improvement in CMT1A mouse models and in patients.Neurology, 2005, 65(5), 681-689.
39. Sahenk, Z.; Chen, L.; Mendell, J. Effects of PMP22 duplication anddeletions on the axonal cytoskeleton. Ann. Neurol., 1999, 45(1), 16-24.
40. Feldman, E. Diabetic neuropathy. Curr. Drug Targets, 2008, 9(1), 1-2.
41. Said, G. Diabetic neuropathy--a review. Nat. Clin. Pract. Neurol., 2007, 3(6), 331-340.
42. Zochodne, D. Diabetes mellitus and the peripheral nervous system:manifestations and mechanisms. Muscle Nerve, 2007, 36(2), 144-166.
43. Boulton, A.; Malik, R.; Arezzo, J.; Sosenko, J. Diabetic somaticneuropathies. Diabetes Care, 2004, 27(6), 1458-1486.
44. Zochodne, D. Diabetic polyneuropathy: an update. Curr. Opin.Neurol., 2008, 21(5), 527-533.
45. Yagihashi, S.; Yamagishi, S.; Wada, R. Pathology and pathogeneticmechanisms of diabetic neuropathy: correlation with clinical signsand symptoms. Diabetes Res. Clin. Pract., 2007, 77(Suppl 1), S184-S189.
46. Llewelyn, J.; Gilbey, S.; Thomas, P.; King, R.; Muddle, J.; Watkins, P. Sural nerve morphometry in diabetic autonomic andpainful sensory neuropathy. A clinicopathological study. Brain, 1991, 114(Pt 2), 867-892.
47. Dyck, P.; Lais, A.; Karnes, J.; O'Brien, P.; Rizza, R. Fiber loss isprimary and multifocal in sural nerves in diabetic polyneuropathy.Ann. Neurol., 1986, 19(5), 425-439.
48. Said, G.; Slama, G.; Selva, J. Progressive centripetal degenerationof axons in small fibre diabetic polyneuropathy. Brain, 1983, 106(Pt 4), 791-807.
49. Behse, F.; Buchthal, F.; Carlsen, F. Nerve biopsy and conductionstudies in diabetic neuropathy. J. Neurol. Neurosurg. Psychiatry, 1977, 40(11), 1072-1082.
50. Fukunaga, M.; Miyata, S.; Liu, B.; Miyazaki, H.; Hirota, Y.; Higo, S.; Hamada, Y.; Ueyama, S.; Kasuga, M. Methylglyoxal inducesapoptosis through activation of p38 MAPK in rat Schwann cells.Biochem. Biophys. Res. Commun., 2004, 320(3), 689-695.
51. Sekido, H.; Suzuki, T.; Jomori, T.; Takeuchi, M.; Yabe-Nishimura, C.; Yagihashi, S. Reduced cell replication and induction ofapoptosis by advanced glycation end products in rat Schwann cells.Biochem. Biophys. Res. Commun., 2004, 320(1), 241-248.
52. Suzuki, T.; Sekido, H.; Kato, N.; Nakayama, Y.; Yabe-Nishimura, C. Neurotrophin-3-induced production of nerve growth factor issuppressed in Schwann cells exposed to high glucose: involvementof the polyol pathway. J. Neurochem., 2004, 91(6), 1430-1438.
53. Leinninger, G.; Backus, C.; Sastry, A.; Yi, Y.; Wang, C.; Feldman, E. Mitochondria in DRG neurons undergo hyperglycemic mediatedinjury through Bim, Bax and the fission protein Drp1. Neurobiol.Dis., 2006, 23(1), 11-22.
54. Russell, J.; Golovoy, D.; Vincent, A.; Mahendru, P.; Olzmann, J.; Mentzer, A.; Feldman, E. High glucose-induced oxidative stressand mitochondrial dysfunction in neurons. FASEB J., 2002, 16(13), 1738-1748.
55. Apfel, S.; Kessler, J.; Adornato, B.; Litchy, W.; Sanders, C.; Rask, C.; NGF Study Group. Recombinant human nerve growth factor inthe treatment of diabetic polyneuropathy. Neurology, 1998, 51(3), 695-702.
56. Apfel, S.; Schwartz, S.; Adornato, B.; Freeman, R.; Biton, V.; Rendell, M.; Vinik, A.; Giuliani, M.; Stevens, J.; Barbano, R.; Dyck, P.J.; rhNGF Clinical Investigator Group. Efficacy and safetyof recombinant human nerve growth factor in patients with diabeticpolyneuropathy, A randomized controlled trial. JAMA, 2000, 284(17), 2215-2221.
57. McArthur, J.; Yiannoutsos, C.; Simpson, D.; Adornato, B.; Singer, E.; Hollander, H.; Marra, C.; Rubin, M.; Cohen, B.; Tucker, T.; Navia, B.A.; Schifitto, G.; Katzenstein, D.; Rask, C.; Zaborski, L.; Smith, M.E.; Shriver, S.; Millar, L.; Clifford, D.B.; Karalnik, I.J.; AIDS Clinical Trials Group Team 291. A phase II trial of nervegrowth factor for sensory neuropathy associated with HIVinfection. Neurology, 2000, 54(5), 1080-1088.
58. Ohi, T.; Saita, K.; Furukawa, S.; Ohta, M.; Hayashi, K.; Matsukura, S. Therapeutic effects of aldose reductase inhibitor on experimentaldiabetic neuropathy through synthesis/secretion of nerve growthfactor. Exp. Neurol., 1998, 151(2), 215-220.
59. Tosaki, T.; Kamiya, H.; Yasuda, Y.; Naruse, K.; Kato, K.; Kozakae, M.; Nakamura, N.; Shibata, T.; Hamada, Y.; Nakashima, E.; Oiso, Y.; Nakamura, J. Reduced NGF secretion by Schwanncells under the high glucose condition decreases neurite outgrowthof DRG neurons. Exp. Neurol., 2008, 213(2), 381-387.
60. Hellweg, R.; Hartung, H. Endogenous levels of nerve growth factor(NGF) are altered in experimental diabetes mellitus, a possible rolefor NGF in the pathogenesis of diabetic neuropathy. J. Neurosci.Res., 1990, 26(2), 258-267.
61. Vo, P.; Tomlinson, D. The regeneration of peripheral noradrenergicnerves after chemical sympathectomy in diabetic rats, effects ofnerve growth factor. Exp. Neurol., 1999, 157(1), 127-134.
62. Schifitto, G.; Yiannoutsos, C.; Simpson, D.; Adornato, B.; Singer, E.; Hollander, H.; Marra, C.; Rubin, M.; Cohen, B.; Tucker, T.; Koralnik, I.J.; Katzenstein, D.; Haidich, B.; Smith, M.E.; Shriver, S.; Millar, L.; Clifford, D.B.; McArthur, J.C.; AIDS Clinical TrialsGroup Team 291. Long-term treatment with recombinant nervegrowth factor for HIV-associated sensory neuropathy. Neurology, 2001, 57(7), 1313-1316.
63. Campana, W.; Myers, R. Exogenous erythropoietin protects againstdorsal root ganglion apoptosis and pain following peripheral nerveinjury. Eur. J. Neurosci., 2003, 18(6), 1497-1506.
64. Gorio, A.; Gokmen, N.; Erbayraktar, S.; Yilmaz, O.; Madaschi, L.; Cichetti, C.; Di Giulio, A.; Vardar, E.; Cerami, A.; Brines, M. Recombinant human erythropoietin counteracts secondary injuryand markedly enhances neurological recovery from experimentalspinal cord trauma. Proc. Natl. Acad. Sci. USA, 2002, 99(14), 9450-9455.
65. Digicaylioglu, M.; Lipton, S. Erythropoietin-mediated neuroprotectioninvolves cross-talk between Jak2 and NF-kappaB signallingcascades. Nature, 2001, 412(6847), 641-647.
66. Sirén, A.; Fratelli, M.; Brines, M.; Goemans, C.; Casagrande, S.; Lewczuk, P.; Keenan, S.; Gleiter, C.; Pasquali, C.; Capobianco, A.; Mennini, T.; Heumann, R.; Cerami, A.; Ehrenreich, H.; Ghezzi, P. Erythropoietin prevents neuronal apoptosis after cerebral ischemiaand metabolic stress. Proc. Natl. Acad. Sci. USA, 2001, 98(7), 4044-4049.
67. Li, X.; Gonias, S.; Campana, W. Schwann cells expresserythropoietin receptor and represent a major target for Epo inperipheral nerve injury. Glia, 2005, 51(4), 254-265.
68. Campana, W.M.; Myers, R.R. Erythropoietin and erythropoietinreceptors in the peripheral nervous system, changes after nerveinjury. FASEB J., 2001, 15(10), 1804-1806.
69. Campana, W.; Li, X.; Shubayev, V.; Angert, M.; Cai, K.; Myers, R. Erythropoietin reduces Schwann cell TNF-alpha.; Walleriandegeneration and pain-related behaviors after peripheral nerveinjury. Eur. J. Neurosci., 2006, 23(3), 617-626.
70. Melli, G.; Jack, C.; Lambrinos, G.; Ringkamp, M.; Höke, A. Erythropoietin protects sensory axons against paclitaxel-induceddistal degeneration. Neurobiol. Dis., 2006, 24(3), 525-530.
71. Bianchi, R.; Buyukakilli, B.; Brines, M.; Savino, C.; Cavaletti, G.; Oggioni, N.; Lauria, G.; Borgna, M.; Lombardi, R.; Cimen, B.; Comelekoglu, U.; Kanik, A.; Tataroglu, C.; Cerami, A.; Ghezzi, P. Erythropoietin both protects from and reverses experimentaldiabetic neuropathy. Proc. Natl. Acad. Sci. USA, 2004, 101(3), 823-828.
72. Leist, M.; Ghezzi, P.; Grasso, G.; Bianchi, R.; Villa, P.; Fratelli, M.; Savino, C.; Bianchi, M.; Nielsen, J.; Gerwien, J.; Kallunki, P.; Larsen, A.K.; Helboe, L.; Christensen, S.; Pedersen, L.O.; Nielsen, M.; Torup, L.; Sager, T.; Sfacteria, A.; Erbayraktar, S.; Erbayraktar, Z.; Gokmen, N.; Yilmaz, O.; Cerami-Hand, C.; Xie, Q.W.; Coleman, T.; Cerami, A.; Brines, M. Derivatives oferythropoietin that are tissue protective but not erythropoietic.Science, 2004, 305(5681), 239-242.
73. Schmidt, R.; Green, K.; Feng, D.; Dorsey, D.; Parvin, C.; Lee, J.; Xiao, Q.; Brines, M. Erythropoietin and its carbamylated derivativeprevent the development of experimental diabetic autonomicneuropathy in STZ-induced diabetic NOD-SCID mice. Exp.Neurol., 2008, 209(1), 161-170.
74. Sereda, M.; Meyer Zu Hörste, M.G.; Suter, U.; Uzma, N.; Nave, K. Therapeutic administration of progesterone antagonist in a modelof Charcot-Marie-Tooth disease (CMT-1A). Nat. Med., 2003, 9(12), 1533-1537.
75. Herrmann, D. Experimental therapeutics in hereditary neuropathies, thepast.; the present.; and the future. Neurotherapeutics, 2008, 5(4), 507-515.
76. Eldridge, C.F.; Bunge, M.B.; Bunge, R.P. Differentiation of axonrelatedSchwann cells in vitro, II. Control of myelin formation bybasal lamina. J. Neurosci., 1989, 9(2), 625-638.
77. Eldridge, C.F.; Bunge, M.B.; Bunge, R.P.; Wood, P.M. Differentiation of axon-related Schwann cells in vitro. I. Ascorbicacid regulates basal lamina assembly and myelin formation. J. CellBiol., 1987, 105(2), 1023-1034.
78. Morrissey, T.K.; Bunge, R.P.; Kleitman, N. Human Schwann cellsin vitro. I. Failure to differentiate and support neuronal health underco-culture conditions that promote full function of rodent cells. J.Neurobiol., 1995, 28(2), 171-189.
79. Lehmann, H.; Köhne, A.; Bernal, F.; Jangouk, P.; Meyer ZuHörste, G.; Dehmel, T.; Hartung, H.; Previtali, S.; Kieseier, B. Matrix metalloproteinase-2 is involved in myelination of dorsalroot ganglia neurons. Glia, 2009, 57(5), 479-489.
80. Passage, E.; Norreel, J.; Noack-Fraissignes, P.; Sanguedolce, V.; Pizant, J.; Thirion, X.; Robaglia-Schlupp, A.; Pellissier, J.; Fontés, M. Ascorbic acid treatment corrects the phenotype of a mousemodel of Charcot-Marie-Tooth disease. Nat. Med., 2004, 10(4), 396-401.
81. Pareyson, D.; Schenone, A.; Fabrizi, G.; Santoro, L.; Padua, L.; Quattrone, A.; Vita, G.; Gemignani, F.; Visioli, F.; Solari, A. Amulticenter.; randomized.; double-blind.; placebo-controlled trial oflong-term ascorbic acid treatment in Charcot-Marie-Tooth diseasetype 1A (CMT-TRIAAL), the study protocol [EudraCT no., 2006-000032-27]. Pharmacol. Res., 2006, 54(6), 436-441.
82. Bunge, M. Bridging the transected or contused adult rat spinal cordwith Schwann cell and olfactory ensheathing glia transplants. Prog.Brain Res., 2002, 137, 275-282.
83. Pearse, D.; Pereira, F.; Marcillo, A.; Bates, M.; Berrocal, Y.; Filbin, M.; Bunge, M. cAMP and Schwann cells promote axonalgrowth and functional recovery after spinal cord injury. Nat. Med., 2004, 10(6), 610-616.
84. Golden, K.; Pearse, D.; Blits, B.; Garg, M.; Oudega, M.; Wood, P.; Bunge, M. Transduced Schwann cells promote axon growth andmyelination after spinal cord injury. Exp. Neurol., 2007, 207(2), 203-217.
85. Pearse, D.; Sanchez, A.; Pereira, F.; Andrade, C.; Puzis, R.; Pressman, Y.; Golden, K.; Kitay, B.; Blits, B.; Wood, P.; Bunge, M.B. Transplantation of Schwann cells and/or olfactoryensheathing glia into the contused spinal cord, Survival.; migration.; axon association.; and functional recovery. Glia, 2007, 55(9), 976-1000.
86. Harvey, A.R.; Chen, M.; Dyson, S.E. Glial cells transplanted to therat optic tract. Influence on the regrowth of retinal axons. Ann. NYAcad. Sci., 1991, 633, 573-576.
87. Maffei, L.; Carmignoto, G.; Perry, V.H.; Candeo, P.; Ferrari, G. Schwann cells promote the survival of rat retinal ganglion cellsafter optic nerve section. Proc. Natl. Acad. Sci. USA, 1990, 87(5), 1855-1859.
88. Strauch, B. Use of nerve conduits in peripheral nerve repair. Hand.Clin., 2000, 16(1), 123-130.
89. Dahlin, L.; Lundborg, G. Use of tubes in peripheral nerve repair.Neurosurg. Clin. N Am., 2001, 12(2), 341-352.
90. Strauch, B.; Rodriguez, D.; Diaz, J.; Yu, H.; Kaplan, G.; Weinstein, D. Autologous Schwann cells drive regeneration through a 6-cmautogenous venous nerve conduit. J. Reconstr. Microsurg., 2001, 17(8), 589-595; discussion: 596-587.
91. Mosahebi, A.; Fuller, P.; Wiberg, M.; Terenghi, G. Effect ofallogeneic Schwann cell transplantation on peripheral nerveregeneration. Exp. Neurol., 2002, 173(2), 213-223.
92. May, F.; Matiasek, K.; Vroemen, M.; Caspers, C.; Mrva, T.; Arndt, C.; Schlenker, B.; Gais, P.; Brill, T.; Buchner, A.; Blesch, A.; Hartung, R.; Stief, C.; Gansbacher, B.; Weidner, N. GDNFtransducedSchwann cell grafts enhance regeneration of erectilenerves. Eur. Urol., 2008, 54(5), 1179-1187.
93. Li, Q.; Ping, P.; Jiang, H.; Liu, K. Nerve conduit filled with GDNFgene-modified Schwann cells enhances regeneration of theperipheral nerve. Microsurgery, 2006, 26(2), 116-121.
94. Rutkowski, J.L.; Kirk, C.J.; Lerner, M.A.; Tennekoon, G.I. Purification and expansion of human Schwann cells in vitro. Nat.Med., 1995, 1(1), 80-83.
95. Morrissey, T.K.; Kleitman, N.; Bunge, R.P. Human Schwann cellsin vitro. II. Myelination of sensory axons following extensivepurification and heregulin-induced expansion. J. Neurobiol., 1995, 28(2), 190-201.
96. Levi, A.D.; Evans, P.J.; Mackinnon, S.E.; Bunge, R.P. Cold storageof peripheral nerves, an in vitro assay of cell viability and function.Glia, 1994, 10(2), 121-131.
97. Morrissey, T.K.; Levi, A.D.; Nuijens, A.; Sliwkowski, M.X.; Bunge, R.P. Axon-induced mitogenesis of human Schwann cellsinvolves heregulin and p185erbB2. Proc. Natl. Acad. Sci. USA, 1995, 92(5), 1431-1435.
98. Amariglio, N.; Hirshberg, A.; Scheithauer, B.W.; Cohen, Y.; Loewenthal, R.; Trakhtenbrot, L.; Paz, N.; Koren-Michowitz, M.; Waldman, D.; Leider-Trejo, L.; Toren, A.; Constantini, S.; Rechavi, G. Donor-derived brain tumor following neural stem celltransplantation in an ataxia telangiectasia patient. PLoS Med., 2009, 6(2), e1000029.